Small-molecule inhibitors of protein–protein interactions: progressing towards the dream
The DOI matches its Crossref record; 180 of the 180 references it cites were found in a registry or an index.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, most of the activities of transcription factors are mediated by protein-protein interaction or binding to DNA in a sequence-specific fashion, both of which are conventionally considered challenging targets for development of small-molecule inhibitors (2).”
From Echinomycin, a small-molecule inhibitor of hypoxia-inducible factor-1 DNA-binding activity. (2005) · cites this paper as [2]
In the citing paper
“Undruggable proteins, which possess flat active sites, often act through PPI networks, which are characterized by large, flat, and undefined interfaces between proteins. These networks have been considered undruggable biological processes for decades.309–311”
From Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials (2023) · cites this paper as [310]
Citations
Cites
In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2
Vassilev, L. T., Vu, B. T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., Kammlott, U., Lukacs, C., Klein, C., et al. (2004) · Science · doi:10.1126/science.1092472 · Cited by 4,661
Nitric oxide synthases: structure, function and inhibition
ALDERTON, W. K., COOPER, C. E., & KNOWLES, R. G. (2001) · Biochemical Journal · doi:10.1042/bj3570593 · Cited by 4,110
The Bcl2 family: regulators of the cellular life-or-death switch
Cory, S., & Adams, J. M. (2002) · Nature Reviews Cancer · doi:10.1038/nrc883 · Cited by 4,032
BCL-2 family members and the mitochondria in apoptosis
Gross, A., McDonnell, J. M., & Korsmeyer, S. J. (1999) · Genes & Development · doi:10.1101/gad.13.15.1899 · Cited by 3,641
Nitric oxide and the immune response
Bogdan, C. (2001) · Nature Immunology · doi:10.1038/ni1001-907 · Cited by 3,447
Ghrelin: Structure and Function
Kojima, M., & Kangawa, K. (2005) · Physiological Reviews · doi:10.1152/physrev.00012.2004 · Cited by 2,810
CTLA-4 can function as a negative regulator of T cell activation
Walunas, T. L., Lenschow, D. J., Bakker, C. Y., Linsley, P. S., Freeman, G. J., Green, J. M., Thompson, C. B., & Bluestone, J. A. (1994) · Immunity · doi:10.1016/1074-7613(94)90071-x · Cited by 2,222
The mechanism of action of cyclosporin A and FK506
Schreiber, S. L., & Crabtree, G. R. (1992) · Immunology Today · doi:10.1016/0167-5699(92)90111-j · Cited by 2,127
Discovering High-Affinity Ligands for Proteins: SAR by NMR
Shuker, S. B., Hajduk, P. J., Meadows, R. P., & Fesik, S. W. (1996) · Science · doi:10.1126/science.274.5292.1531 · Cited by 2,041
Anatomy of hot spots in protein interfaces
Bogan, A. A., & Thorn, K. S. (1998) · Journal of Molecular Biology · doi:10.1006/jmbi.1998.1843 · Cited by 1,988
Research works printed but not linked: 4
- Das, R. C. & Morrow, K. J. J. in Antibody Engineering Report (Drug and Market Development Publications, 2002).
- Gibson, C. et al. Nonpeptidic α(v)β(3) Integrin antagonist libraries: on-bead screening and mass spectrometric identification without tagging. Angew. Chem. Int. Ed. Engl. 40, 165–169 (2001). · doi:10.1002/1521-3773(20010105)40:1<165::aid-anie165>3.0.co;2-8
- Raimundo, B. C. et al. Discovery of small-molecule inhibitors of interleukin-2 using fragment assembly. J. Med. Chem. (in the press). References 56–59 (and 62 below) detail an interdisciplinary approach, integrating fragment-based discovery, medicinal chemistry, and structural biology, to discovering inhibitors of the IL-2/IL-2R interaction.
- Hajduk, P. J. et al. High-throughput nuclear magnetic resonance-based screening. J. Med. Chem. 42, 2315–2317 (1999). · DOI · Paper page
Cited by
Vogelstein, B., Papadopoulos, N., Velculescu, V. E., Zhou, S., Diaz, L. A., & Kinzler, K. W. (2013) · Science · doi:10.1126/science.1235122 · Cited by 7,863
Molecular Docking and Structure-Based Drug Design Strategies
Ferreira, L., Dos Santos, R., Oliva, G., & Andricopulo, A. (2015) · Molecules · doi:10.3390/molecules200713384 · Cited by 2,528
“Many diseases, such as cancer, can be attributed to defective protein-protein interactions (PPIs); therefore, this type of intermolecular event is a highly attractive target in drug discovery [115].”
BackgroundThe re-emergence of natural products for drug discovery in the genomics era
Harvey, A. L., Edrada-Ebel, R., & Quinn, R. J. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4510 · Cited by 2,572
Reaching for high-hanging fruit in drug discovery at protein–protein interfaces
Wells, J. A., & McClendon, C. L. (2007) · Nature · doi:10.1038/nature06526 · Cited by 1,960
Self-citationClick Chemistry for Drug Development and Diverse Chemical–Biology Applications
Thirumurugan, P., Matosiuk, D., & Jozwiak, K. (2013) · Chemical Reviews · doi:10.1021/cr200409f · Cited by 1,896
Intrinsically Disordered Proteins in Human Diseases: Introducing the D2Concept
Uversky, V. N., Oldfield, C. J., & Dunker, A. K. (2008) · Annual Review of Biophysics · doi:10.1146/annurev.biophys.37.032807.125924 · Cited by 1,410
Understanding protein non-folding
Uversky, V. N., & Dunker, A. K. (2010) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2010.01.017 · Cited by 1,186
“In addition to nutlins, seven other promising drug molecules have been found that act by blocking protein-protein interactions [346,347].”
BackgroundSmall-Molecule Inhibitors of Protein-Protein Interactions: Progressing toward the Reality
Arkin, M. R., Tang, Y., & Wells, J. A. (2014) · Chemistry & Biology · doi:10.1016/j.chembiol.2014.09.001 · Cited by 1,065
Self-citationNavigating chemical space for biology and medicine
Lipinski, C., & Hopkins, A. (2004) · Nature · doi:10.1038/nature03193 · Cited by 1,002
“Examples of such proteins are the many proteins that participate in protein–protein interactions in biological signalling cascade”
Lu, H., Zhou, Q., He, J., Jiang, Z., Peng, C., Tong, R., & Shi, J. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00315-3 · Cited by 891
Structure and dynamics of molecular networks: A novel paradigm of drug discovery
Csermely, P., Korcsmáros, T., Kiss, H. J. M., London, G., & Nussinov, R. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.01.016 · Cited by 892
“Development of drugs targeting network edges (recently called: edgetic drugs) has a number of advantages (Arkin & Wells, 2004; Keskin et al., 2007; Sugaya et al., 2007; Dreze et al., 2009; Zhong et al., 2009; Schlecht et al., 2012; Wang et al., 2012b).”
BackgroundSLC6 Neurotransmitter Transporters: Structure, Function, and Regulation
Kristensen, A. S., Andersen, J., Jørgensen, T. N., Sørensen, L., Eriksen, J., Loland, C. J., Strømgaard, K., & Gether, U. (2011) · Pharmacological Reviews · doi:10.1124/pr.108.000869 · Cited by 864
Hot spots—A review of the protein–protein interface determinant amino‐acid residues
Moreira, I. S., Fernandes, P. A., & Ramos, M. J. (2007) · Proteins: Structure, Function, and Bioinformatics · doi:10.1002/prot.21396 · Cited by 760
Genome-wide RNAi screen identifies human host factors crucial for influenza virus replication
Karlas, A., Machuy, N., Shin, Y., Pleissner, K.-P., Artarini, A., Heuer, D., Becker, D., Khalil, H., Ogilvie, L. A., Hess, S., et al. (2010) · Nature · doi:10.1038/nature08760 · Cited by 695
Structure-based maximal affinity model predicts small-molecule druggability
Cheng, A. C., Coleman, R. G., Smyth, K. T., Cao, Q., Soulard, P., Caffrey, D. R., Salzberg, A. C., & Huang, E. S. (2007) · Nature Biotechnology · doi:10.1038/nbt1273 · Cited by 695
“The current method is meant to address only the specified binding site and does not take into account the possibility of substantial flexibility or inhibition at allosteric pockets, both of which are important considerations in drug desig”
MethodFoldamers with Heterogeneous Backbones
Horne, W. S., & Gellman, S. H. (2008) · Accounts of Chemical Research · doi:10.1021/ar800009n · Cited by 689
The unfoldomics decade: an update on intrinsically disordered proteins
Dunker, A. K., Oldfield, C. J., Meng, J., Romero, P., Yang, J. Y., Chen, J., Vacic, V., Obradovic, Z., & Uversky, V. N. (2008) · BMC Genomics · doi:10.1186/1471-2164-9-s2-s1 · Cited by 670
Multifaceted Roles of Disulfide Bonds. Peptides as Therapeutics
Góngora-Benítez, M., Tulla-Puche, J., & Albericio, F. (2014) · Chemical Reviews · doi:10.1021/cr400031z · Cited by 655
Drug discovery in the ubiquitin–proteasome system
Nalepa, G., Rolfe, M., & Harper, J. W. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2056 · Cited by 608
Diversity-oriented synthesis: Exploring the intersections between chemistry and biology
Tan, D. S. (2005) · Nature Chemical Biology · doi:10.1038/nchembio0705-74 · Cited by 605
“Moreover, protein-protein interactions, which have historically been very difficult targets for synthetic drug”
BackgroundNeri, D., & Bicknell, R. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1627 · Cited by 600
Moerke, N. J., Aktas, H., Chen, H., Cantel, S., Reibarkh, M. Y., Fahmy, A., Gross, J. D., Degterev, A., Yuan, J., Chorev, M., et al. (2007) · Cell · doi:10.1016/j.cell.2006.11.046 · Cited by 572
“An increasingly important strategy in chemical genetics is the identification of compounds that disrupt specific proteinprotein interactions (Arkin and Wells, 2004).”
Kell, D. B. (2009) · BMC Medical Genomics · doi:10.1186/1755-8794-2-2 · Cited by 554
“ions (e.g. [700]) cholesterol is a poor predictor of cardiovascular disease. However, a known target of statins different from HMGCoA reductase is the β2-integrin leukocyte function antigen-1 (LFA-1) [701; 702] and in this context, it is important to note that the clinical benefits of the statins are certainly not due…”
BackgroundMDM2 inhibitors for cancer therapy
Vassilev, L. T. (2007) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2006.11.002 · Cited by 532
On the binding affinity of macromolecular interactions: daring to ask why proteins interact
Kastritis, P. L., & Bonvin, A. M. J. J. (2013) · Journal of The Royal Society Interface · doi:10.1098/rsif.2012.0835 · Cited by 520
“Over the last 20 years, this approach has yielded on a daily basis fascinating results in both fundamental [33–39] and applied [40–43] research.”
Echinomycin, a small-molecule inhibitor of hypoxia-inducible factor-1 DNA-binding activity.
Kong, D., Park, E. J., Stephen, A. G., Calvani, M., Cardellina, J. H., Monks, A., Fisher, R. J., Shoemaker, R. H., & Melillo, G. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-1235 · Cited by 508
“However, most of the activities of transcription factors are mediated by protein-protein interaction or binding to DNA in a sequence-specific fashion, both of which are conventionally considered challenging targets for development of small-molecule inhibitors (2).”
BackgroundA decade and a half of protein intrinsic disorder: Biology still waits for physics
Uversky, V. N. (2013) · Protein Science · doi:10.1002/pro.2261 · Cited by 499
“In addition to nutlins inhibiting p53-Mdm2 interaction, several other small molecules also act by blocking protein– protein interactions.(272,273) Some of these interactions involve one structured partner and one disordered partner, with disordered segments becoming a-helix”
BackgroundModulators of Protein–Protein Interactions
Milroy, L.-G., Grossmann, T. N., Hennig, S., Brunsveld, L., & Ottmann, C. (2014) · Chemical Reviews · doi:10.1021/cr400698c · Cited by 497
Protac-Induced Protein Degradation in Drug Discovery: Breaking the Rules or Just Making New Ones?
Churcher, I. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b01272 · Cited by 491
Discovery of Small Molecules that Bind to K‐Ras and Inhibit Sos‐Mediated Activation
Sun, Q., Burke, J. P., Phan, J., Burns, M. C., Olejniczak, E. T., Waterson, A. G., Lee, T., Rossanese, O. W., & Fesik, S. W. (2012) · Angewandte Chemie International Edition · doi:10.1002/anie.201201358 · Cited by 490
Christ, F., Voet, A., Marchand, A., Nicolet, S., Desimmie, B. A., Marchand, D., Bardiot, D., Van der Veken, N. J., Van Remoortel, B., Strelkov, S. V., et al. (2010) · Nature Chemical Biology · doi:10.1038/nchembio.370 · Cited by 479
“Genome and proteome analyses highlight the key role of PPIs in biological processes; thus, PPIs represent a large and important class of therapeutic target”
BackgroundComplement-targeted therapeutics
Ricklin, D., & Lambris, J. D. (2007) · Nature Biotechnology · doi:10.1038/nbt1342 · Cited by 481
“Traditional drug discovery aims for small molecular entities with the potential for oral administration, yet many critical steps in the complement cascade are fundamentally based on large protein-protein interactions, which are challenging to influence with small molecule”
BackgroundStrategies for Targeting Protein–Protein Interactions With Synthetic Agents
Yin, H., & Hamilton, A. D. (2005) · Angewandte Chemie International Edition · doi:10.1002/anie.200461786 · Cited by 453
Structural basis for small molecule targeting of the programmed death ligand 1 (PD-L1)
Zak, K. M., Grudnik, P., Guzik, K., Zieba, B. J., Musielak, B., Dömling, A., Dubin, G., & Holak, T. A. (2016) · Oncotarget · doi:10.18632/oncotarget.8730 · Cited by 422
“The most important finding of this study is in unambiguous definition of the druggable “hot spots” [30-32] at the surface of PD-L1 suitable for targeting with low-molecular weight inhibitors.”
Diversity-oriented synthesis: producing chemical tools for dissecting biology
O' Connor, C. J., Beckmann, H. S. G., & Spring, D. R. (2012) · Chemical Society Reviews · doi:10.1039/c2cs35023h · Cited by 434
Constraining Cyclic Peptides To Mimic Protein Structure Motifs
Hill, T. A., Shepherd, N. E., Diness, F., & Fairlie, D. P. (2014) · Angewandte Chemie International Edition · doi:10.1002/anie.201401058 · Cited by 418
Ubiquitin and ubiquitin-like proteins in cancer pathogenesis
Hoeller, D., Hecker, C.-M., & Dikic, I. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1994 · Cited by 408
“The major breakthrough was based on findings that the binding energy of protein–protein interactions is localized around a small number of amino-acid residues, so-called 'hot spots”
BackgroundRecent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials
Xie, X., Yu, T., Li, X., Zhang, N., Foster, L. J., Peng, C., Huang, W., & He, G. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01589-z · Cited by 396
Ramsey, H. E., Fischer, M. A., Lee, T., Gorska, A. E., Arrate, M. P., Fuller, L., Boyd, K. L., Strickland, S. A., Sensintaffar, J., Hogdal, L. J., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0140 · Cited by 379
“Although MCL1 was considered a particularly difficult protein to target with small molecules (45), several groups have recently discovered potent MCL1 inhibitors (46–48).”
BackgroundInterleukin‐13: Targeting an underestimated cytokine in atopic dermatitis
Bieber, T. (2020) · Allergy · doi:10.1111/all.13954 · Cited by 382
Fluorescence polarization assays in small molecule screening
Lea, W. A., & Simeonov, A. (2011) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2011.537322 · Cited by 379
“The debate over whether PPIs are druggable or not is largely due to the fact that they are characterized by large and ill-defined interfaces with variable contact points and a lack of deep and welldefined binding cavities [67].”
BackgroundNanotechnology, nanomedicine, and the development of new, effective therapies for cancer
Kawasaki, E. S., & Player, A. (2005) · Nanomedicine: Nanotechnology, Biology and Medicine · doi:10.1016/j.nano.2005.03.002 · Cited by 368
“[63] Arkin MR, Wells JA.”
BackgroundG protein βγ subunits: Central mediators of G protein-coupled receptor signaling
Smrcka, A. V. (2008) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-008-8006-5 · Cited by 365
Verdine, G. L., & Walensky, L. D. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-2184 · Cited by 361
Targeting Cyclin-Dependent Kinases in Human Cancers: From Small Molecules to Peptide Inhibitors
Peyressatre, M., Prével, C., Pellerano, M., & Morris, M. (2015) · Cancers · doi:10.3390/cancers7010179 · Cited by 344
Alex, A., Millan, D. S., Perez, M., Wakenhut, F., & Whitlock, G. A. (2011) · MedChemComm · doi:10.1039/c1md00093d · Cited by 329
Schmidtke, P., & Barril, X. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm100574m · Cited by 331
Searching for new allosteric sites in enzymes
Hardy, J. A., & Wells, J. A. (2004) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2004.10.009 · Cited by 329
Self-citationRecent Progress and Future Directions in Protein-Protein Docking
Ritchie, D. (2008) · Current Protein & Peptide Science · doi:10.2174/138920308783565741 · Cited by 316
“1389-2037/08 $55.00+.00 © 2008 Bentham Science Publishers Ltd. Keywords: Protein-protein docking, protein-protein interactions, docking algorithms, data-driven docking, molecular dynamics, protein structure databases, protein interface prediction, CAPRI.”
InfluentialLimiting inflammatory responses during activation of innate immunity
Han, J., & Ulevitch, R. J. (2005) · Nature Immunology · doi:10.1038/ni1274 · Cited by 315
“Although developing small molecules that modulate protein-protein interaction is difficult, progress in this field has attracted much attentio”
BackgroundPredicting druggable binding sites at the protein–protein interface
Fuller, J. C., Burgoyne, N. J., & Jackson, R. M. (2009) · Drug Discovery Today · doi:10.1016/j.drudis.2008.10.009 · Cited by 310
Kim, J., Kim, H., & Park, S. B. (2014) · Journal of the American Chemical Society · doi:10.1021/ja508343a · Cited by 308
Therapeutics targeting the innate immune system
Ulevitch, R. J. (2004) · Nature Reviews Immunology · doi:10.1038/nri1396 · Cited by 309
“Many researchers, including Wells and his co-worker”
History of protein–protein interactions: From egg‐white to complex networks
Braun, P., & Gingras, A. (2012) · PROTEOMICS · doi:10.1002/pmic.201100563 · Cited by 308
“The general goal is to identify so-called hot spots on the surface that either contribute a large portion of the total binding energy, or are amenable to steric interference with a small molecule compound [261].”
BackgroundA surface on the androgen receptor that allosterically regulates coactivator binding
Estébanez-Perpiñá, E., Arnold, L. A., Nguyen, P., Rodrigues, E. D., Mar, E., Bateman, R., Pallai, P., Shokat, K. M., Baxter, J. D., Guy, R. K., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0708036104 · Cited by 307
Small‐Molecule Inhibitors of the Interaction between the E3 Ligase VHL and HIF1α
Buckley, D. L., Gustafson, J. L., Van Molle, I., Roth, A. G., Tae, H. S., Gareiss, P. C., Jorgensen, W. L., Ciulli, A., & Crews, C. M. (2012) · Angewandte Chemie International Edition · doi:10.1002/anie.201206231 · Cited by 302
MTiOpenScreen: a web server for structure-based virtual screening
Labbé, C. M., Rey, J., Lagorce, D., Vavruša, M., Becot, J., Sperandio, O., Villoutreix, B. O., Tufféry, P., & Miteva, M. A. (2015) · Nucleic Acids Research · doi:10.1093/nar/gkv306 · Cited by 292
Assessing Helical Protein Interfaces for Inhibitor Design
Bullock, B. N., Jochim, A. L., & Arora, P. S. (2011) · Journal of the American Chemical Society · doi:10.1021/ja206074j · Cited by 300
Gaussian accelerated molecular dynamics: Principles and applications
Wang, J., Arantes, P. R., Bhattarai, A., Hsu, R. V., Pawnikar, S., Huang, Y. M., Palermo, G., & Miao, Y. (2021) · WIREs Computational Molecular Science · doi:10.1002/wcms.1521 · Cited by 295
“136 Here, we will summarize recent GaMD applications in simulation studies of PPIs and protein – peptide interactions.”
BackgroundA practical view of ‘druggability’
Keller, T. H., Pichota, A., & Yin, Z. (2006) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2006.06.014 · Cited by 295
Chen, J., Sawyer, N., & Regan, L. (2013) · Protein Science · doi:10.1002/pro.2230 · Cited by 301
Walsh, D. P., & Chang, Y.-T. (2006) · Chemical Reviews · doi:10.1021/cr0404141 · Cited by 296
Discovery of a Potent Inhibitor of the Antiapoptotic Protein Bcl-x L from NMR and Parallel Synthesis
Petros, A. M., Dinges, J., Augeri, D. J., Baumeister, S. A., Betebenner, D. A., Bures, M. G., Elmore, S. W., Hajduk, P. J., Joseph, M. K., Landis, S. K., et al. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm0507532 · Cited by 292
Modulating protein–protein interactions: the potential of peptides
Nevola, L., & Giralt, E. (2015) · Chemical Communications · doi:10.1039/c4cc08565e · Cited by 289
Recent Advances in Nanoparticle-Based Cancer Drug and Gene Delivery
(2018) · Advances in Cancer Research · doi:10.1016/bs.acr.2017.11.003 · Cited by 288
“Once the inhibitor enters the cells, it affects various other molecules, such as proteins, and ultimately kills cancer cells (Arkin & Wells, 2004).”
BackgroundStructural and biological mimicry of protein surface recognition by α/β-peptide foldamers
Horne, W. S., Johnson, L. M., Ketas, T. J., Klasse, P. J., Lu, M., Moore, J. P., & Gellman, S. H. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0902663106 · Cited by 275
“Protein-protein associations are often resistant to inhibition by small molecules because the contact surfaces on the natural partners are large (1).”
BackgroundCimermancic, P., Weinkam, P., Rettenmaier, T. J., Bichmann, L., Keedy, D. A., Woldeyes, R. A., Schneidman-Duhovny, D., Demerdash, O. N., Mitchell, J. C., Wells, J. A., et al. (2016) · Journal of Molecular Biology · doi:10.1016/j.jmb.2016.01.029 · Cited by 268
“For example, large and flat interfaces between interacting proteins were considered undruggable, although several examples of protein interfaces undergoing a conformational change coupled with binding a small molecule were recently described [18,19].”
BackgroundSelf-citationJeon, J.-H., Javanainen, M., Martinez-Seara, H., Metzler, R., & Vattulainen, I. (2016) · Physical Review X · doi:10.1103/physrevx.6.021006 · Cited by 275
“Therefore, understanding and thereafter altering the dynamics that govern the formation of functional protein– protein [69,70], lipid–protein [71,72], or domain–protein [73] units is an intriguing approach to the treatment of numerous diseases.”
BackgroundComputational Fragment-Based Binding Site Identification by Ligand Competitive Saturation
Guvench, O., & MacKerell, A. D. (2009) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1000435 · Cited by 271
“In reality, proteins can accommodate ligands by undergoing conformational changes [14,15], and water plays an important role in protein:ligand binding affinity [16–18].”
BackgroundMultivalent Small-Molecule Pan-RAS Inhibitors
Welsch, M. E., Kaplan, A., Chambers, J. M., Stokes, M. E., Bos, P. H., Zask, A., Zhang, Y., Sanchez-Martin, M., Badgley, M. A., Huang, C. S., et al. (2017) · Cell · doi:10.1016/j.cell.2017.02.006 · Cited by 274
Computational alanine scanning mutagenesis—An improved methodological approach
Moreira, I. S., Fernandes, P. A., & Ramos, M. J. (2007) · Journal of Computational Chemistry · doi:10.1002/jcc.20566 · Cited by 273
Advances in targeting cell surface signalling molecules for immune modulation
Yao, S., Zhu, Y., & Chen, L. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd3877 · Cited by 267
Cell-division inhibitors: new insights for future antibiotics
Lock, R. L., & Harry, E. J. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2510 · Cited by 263
“Targeting protein–protein interactions though is challenging; however, new developments in the discovery of small molecules that inhibit such interactions are progressing wel”
BackgroundPatgiri, A., Jochim, A. L., & Arora, P. S. (2008) · Accounts of Chemical Research · doi:10.1021/ar700264k · Cited by 251
Structural basis for the specific inhibition of heterotrimeric G q protein by a small molecule
Nishimura, A., Kitano, K., Takasaki, J., Taniguchi, M., Mizuno, N., Tago, K., Hakoshima, T., & Itoh, H. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1003553107 · Cited by 252
“The unique binding mode of YM-254890 to Gq is reminiscent of that of the “interfacial inhibitor,” which is an alternative to a competitive inhibitor in the development of innovative therapeutics (27, 28).”
BackgroundRational drug design via intrinsically disordered protein
Cheng, Y., LeGall, T., Oldfield, C. J., Mueller, J. P., Van, Y.-Y. J., Romero, P., Cortese, M. S., Uversky, V. N., & Dunker, A. K. (2006) · Trends in Biotechnology · doi:10.1016/j.tibtech.2006.07.005 · Cited by 250
Ohoka, N., Okuhira, K., Ito, M., Nagai, K., Shibata, N., Hattori, T., Ujikawa, O., Shimokawa, K., Sano, O., Koyama, R., et al. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.768853 · Cited by 240
“However, there are many pathogenic proteins without enzymatic activity to which pharmacological inhibitors can hardly be developed (2, 3).”
BackgroundThe biology of IQGAP proteins: beyond the cytoskeleton
Hedman, A. C., Smith, J. M., & Sacks, D. B. (2015) · EMBO reports · doi:10.15252/embr.201439834 · Cited by 245
Binding Site Detection and Druggability Index from First Principles
Seco, J., Luque, F. J., & Barril, X. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm801385d · Cited by 239
Modulation of Protein–Protein Interactions for the Development of Novel Therapeutics
Petta, I., Lievens, S., Libert, C., Tavernier, J., & De Bosscher, K. (2016) · Molecular Therapy · doi:10.1038/mt.2015.214 · Cited by 240
Nie, Q., Du, X.-G., & Geng, M.-Y. (2011) · Acta Pharmacologica Sinica · doi:10.1038/aps.2011.14 · Cited by 234
Cyclin-dependent protein kinase inhibitors including palbociclib as anticancer drugs
Roskoski, R. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2016.03.012 · Cited by 237
Discovery of an allosteric site in the caspases
Hardy, J. A., Lam, J., Nguyen, J. T., O'Brien, T., & Wells, J. A. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0404781101 · Cited by 239
Self-citationMultiple Independent Binding Sites for Small-Molecule Inhibitors on the Oncoprotein c-Myc
Hammoudeh, D. I., Follis, A. V., Prochownik, E. V., & Metallo, S. J. (2009) · Journal of the American Chemical Society · doi:10.1021/ja900616b · Cited by 229
Differential Targeting of Gßγ-Subunit Signaling with Small Molecules
Bonacci, T. M., Mathews, J. L., Yuan, C., Lehmann, D. M., Malik, S., Wu, D., Font, J. L., Bidlack, J. M., & Smrcka, A. V. (2006) · Science · doi:10.1126/science.1120378 · Cited by 230
Chemical probes and drug leads from advances in synthetic planning and methodology
Gerry, C. J., & Schreiber, S. L. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.53 · Cited by 230
Ocana, A., Pandiella, A., Privat, C., Bravo, I., Luengo-Oroz, M., Amir, E., & Gyorffy, B. (2025) · Biomarker Research · doi:10.1186/s40364-025-00758-2 · Cited by 187
“Some proteins involved in large protein-protein interactions, have large, flat surfaces that do not easily accommodate small molecules, and others can have highly flexible or dynamic structures which makes binding difficult [23].”
Current Therapeutic Options in the Treatment of Rheumatoid Arthritis
Köhler, B. M., Günther, J., Kaudewitz, D., & Lorenz, H.-M. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8070938 · Cited by 215
Transient Pockets on Protein Surfaces Involved in Protein−Protein Interaction
Eyrisch, S., & Helms, V. (2007) · Journal of Medicinal Chemistry · doi:10.1021/jm070095g · Cited by 213
Inhibition of Mcl-1 through covalent modification of a noncatalytic lysine side chain
Akçay, G., Belmonte, M. A., Aquila, B., Chuaqui, C., Hird, A. W., Lamb, M. L., Rawlins, P. B., Su, N., Tentarelli, S., Grimster, N. P., et al. (2016) · Nature Chemical Biology · doi:10.1038/nchembio.2174 · Cited by 207
Thiel, P., Kaiser, M., & Ottmann, C. (2012) · Angewandte Chemie International Edition · doi:10.1002/anie.201107616 · Cited by 207
Targeting the p53–MDM2 interaction to treat cancer
Klein, C., & Vassilev, L. T. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6602164 · Cited by 204
“However, protein– protein interactions have long been viewed as high-risk targets due to the fact that proteins generally offer relatively large and flat interacting surfaces that are not readily disturbed by small-molecule drugs (Arkin and Wells, 2004).”
BackgroundAbundance of Intrinsic Disorder in Protein Associated with Cardiovascular Disease
Cheng, Y., LeGall, T., Oldfield, C. J., Dunker, A. K., & Uversky, V. N. (2006) · Biochemistry · doi:10.1021/bi060981d · Cited by 208
Rationalizing the chemical space of protein–protein interaction inhibitors
Sperandio, O., Reynès, C. H., Camproux, A.-C., & Villoutreix, B. O. (2010) · Drug Discovery Today · doi:10.1016/j.drudis.2009.11.007 · Cited by 202
Lifitegrast, a Novel Integrin Antagonist for Treatment of Dry Eye Disease
Perez, V. L., Pflugfelder, S. C., Zhang, S., Shojaei, A., & Haque, R. (2016) · The Ocular Surface · doi:10.1016/j.jtos.2016.01.001 · Cited by 201
RVX-208, an Inducer of ApoA-I in Humans, Is a BET Bromodomain Antagonist
McLure, K. G., Gesner, E. M., Tsujikawa, L., Kharenko, O. A., Attwell, S., Campeau, E., Wasiak, S., Stein, A., White, A., Fontano, E., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0083190 · Cited by 198
“However, many of these inhibitors do not follow traditional Lipinski rules for what makes a successful small molecule, orally bioavailable drug, since they very often are of higher molecular weight [38].”
BackgroundMaking protein interactions druggable: targeting PDZ domains
Dev, K. K. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1578 · Cited by 197
“A number of reviews have recently described the structural and chemical intricacies involved in developing small molecules that modulate protein–protein interaction”
BackgroundBlazer, L. L., & Neubig, R. R. (2009) · Neuropsychopharmacology · doi:10.1038/npp.2008.151 · Cited by 197
“These regions are often relatively featureless expanses of protein surface that cover 750–1500 Å(2) (Arkin and Wells, 2004) and are devoid of traditional ‘pockets’ into which a small molecule can dock in an energetically favorable manner.”
BackgroundThe molecular architecture of protein–protein binding sites
Reichmann, D., Rahat, O., Cohen, M., Neuvirth, H., & Schreiber, G. (2007) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2007.01.004 · Cited by 197
Challenges of antibacterial discovery revisited
Gwynn, M. N., Portnoy, A., Rittenhouse, S. F., & Payne, D. J. (2010) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2010.05828.x · Cited by 193
Metadata
- Authors
- Arkin, M. R., & Wells, J. A.
- Affiliations
- Sunesis (United States) (US)
- Venue
- Nature Reviews Drug Discovery
- Published
- 2004-04
- Volume
- 3
- Issue
- 4
- Pages
- 301-317
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2167398093
- Cited by
- 1,705
- References
- 178
- Citations by year
- 2026: 52 · 2025: 48 · 2024: 39 · 2023: 51 · 2022: 46 · 2021: 61 · 2020: 54 · 2019: 71 · 2018: 73 · 2017: 61 · 2016: 99 · 2015: 101 · 2014: 126 · 2013: 110 · 2012: 110
- FWCI
- 5.99
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Physical Sciences › Chemistry › Organic Chemistry › Chemical Synthesis and Analysis
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Keywords
- protein-protein interaction, small molecule inhibitors, drug discovery, binding pocket, therapeutic target, inhibitor characterization
- MeSH terms
- Animals, Binding Sites, Enzyme Inhibitors, Humans, Protein Binding, Proteins, Receptors, Cell Surface, Drug Design, Computational Biology
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.